'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
"This is one of those situations that is very difficult," Cramer on On CNBC's "Mad Money Lightning Round," Jim Cramer said, "This is a very speculative situation," when asked about ADMA Biologics, Inc. (NASDAQ:ADMA). "Any time there's immunity-compromised patients, there's some big money down the road," he added.
CNBC的“疯狂金钱闪电轮”的吉姆·克莱默表示，当被问及ADMA生物制品公司（纳斯达克：ADMA）时说：“这是一个非常投机的情况。”他补充说：“每当有免疫受损的患者时，未来就会涌入一些大笔资金。”
On Aug. 8, ADMA Biologics reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates.
ADMA生物制品公司报告了超出预期的第二季度财务业绩，并将FY24和FY25营业收入指引提高至估计之上。
The company reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 7 cents per share. The company reported quarterly sales of about $107.2 million which beat the analyst consensus estimate of $86.4 million.
该公司报告了每股13分的季度收益，超过了分析师共识估价的7分。该公司报告的季度销售额约为10720万美元，超过了分析师共识估价的8640万美元。
"This is one of those situations that is very difficult," Cramer on MP Materials Corp. (NYSE:MP). "If they don't pull out of the tailspin of losses, then it just doesn't matter."
克莱默在MP材料公司（纽约证券交易所：MP）上表示：“这是一种非常困难的情况。”“如果他们无法摆脱亏损的困境，那就没什么意义了。”
On July 25, Marine Prods posted better-than-expected sales for its second quarter. Marine Prods reported quarterly earnings of 14 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $69.55 million which beat the analyst consensus estimate of $65.35 million.
7月25日，Marine Prods发布了第二季度超出预期的销售业绩。Marine Prods报告的每股季度收益为14美分，与分析师共识估价相符。该公司报告的季度销售额为6955万美元，超过了分析师共识估价的6535万美元。
When asked about Delcath Systems (NASDAQ:DCTH), he said, "There's no investing. At this point, it is speculating."
当被问及迪卡斯系统（纳斯达克：DCTH）时，他表示：“这不是投资。目前，这只是投机。”
On Aug. 28, Delcath Systems announced positive results from independent study on liver-directed therapy for uveal melanoma patients.
8月28日，迪卡斯系统宣布了对葡萄膜黑色素瘤患者进行的肝定向疗法独立研究的积极结果。
Price Action:
价格行动：
- ADMA Biologics shares fell 0.1% to settle at $17.22 on Thursday.
- MP Materials shares gained 3.2% to close at $12.90.
- Delcath Systems shares gained 1.2% to close at $10.77.
- adma biologics股票周四下跌0.1%，收于17.22美元。
- mp materials股票上涨3.2%，收盘价为12.90美元。
- 迪卡斯股票上涨1.2%，收盘价10.77美元。
Read Next:
阅读下一篇：
- Top 2 Materials Stocks That Are Ticking Portfolio Bombs
- 前两只可疑的材料股，会让你投资组合拆弹
Image: Shutterstock
图片：shutterstock